Newsroom

SANTIAGO, Chile--(BUSINESS WIRE)--Cencosud today announced the acquisition of 100% of Makro Supermayorista in Colombia, reinforcing its growth in the region and its positioning in the Cash & Carry format. The transaction, carried out through its subsidiary Cencosud Internacional SpA, involves an estimated investment of US$158 million, fully financed with the company’s own resources. Makro has more than 25 years of experience in Colombia and operates 21 stores in 16 cities, including Bogotá,...

TORONTO--(BUSINESS WIRE)--Western Metallica Resources Corp. (TSXV: WMS) (“Western Metallica” or the “Company”) announces the results of its Annual General and Special Meeting of Shareholders held on June 25, 2026 (the “Meeting”). Over 12% of the Company’s shares were represented at the Meeting. Detailed results of the vote for the election of Directors held virtually at the Meeting on June 25, 2026, are set out below: Board of Director Nominees % Votes For % Votes Withheld Gregory Duras 94.43 5...

WALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biotechnology company focused on discovering, developing, and commercializing potentially best-in-class medicines for autoimmune and rare diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved Lumvoa™ (veligrotug-vvze) for the treatment of thyroid eye disease (TED). TED is a rare, debilitating autoimmune disease characterized by inflammation and tissue remodeling around and behind the...

CIDADE DO MÉXICO--(BUSINESS WIRE)--AM Best afirmou o Financial Strength Rating A- (Excelente) e o Rating de Crédito de Emissor de Longo Prazo "a-" (Excelente) da Liberty Mutual Surety Brasil Seguros S.A. (LMSB) (São Paulo, Brasil). A perspectiva desses Ratings de Crédito (ratings) é estável. Os ratings refletem a solidez do balanço patrimonial da LMSB, que a AM Best avalia como forte, bem como seu desempenho operacional adequado, perfil empresarial limitado e gestão de risco da empresa (ERM) ap...

NEW YORK & NEW ORLEANS--(BUSINESS WIRE)--Kahn Swick & Foti, LLC (“KSF”) and KSF partner, the former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until June 30, 2026 to file lead plaintiff applications in a securities class action lawsuit against Activision Blizzard Inc. (“Activision” or the "Company") (NasdaqGM: ATVI), if they sold Activision common stock between January 18, 2022 and October 13, 2023, inclusive (the “Class Period”) (excluding those tha...

GRAPEVINE, Texas--(BUSINESS WIRE)--GameStop Corp. (NYSE: GME) (“GameStop” or the “Company”) today announced that, for the fiscal year ending January 30, 2027 ("fiscal year 2026"), the Company currently expects to generate Adjusted EBITDA in excess of $600 million, compared to Adjusted EBITDA of $345.4 million in fiscal year 2025. GameStop's leadership team remains focused on advancing the proposed acquisition of eBay, Inc. ("eBay"). Additional materials regarding the proposed transaction are fo...

MORGES, Schweiz--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) gab heute bekannt, dass der Ausschuss für Humanarzneimittel (CHMP) der Europäischen Arzneimittelagentur (EMA) eine positive Stellungnahme abgegeben und die Zulassung von Opzelura® (Ruxolitinib)-Creme zur Behandlung von mittelschwerer atopischer Dermatitis (AD) bei erwachsenen Patienten, bei denen topische Kortikosteroide (TCS) und topische Calcineurin-Hemmer (TCI) unzureichend oder ungeeignet sind, empfohlen hat. „AD ist eine chronische Ha...

MORGES, Zwitserland--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) heeft vandaag bekendgemaakt dat het Comité voor geneesmiddelen voor menselijk gebruik (CHMP) van het Europees Geneesmiddelenbureau (EMA) een positief advies heeft uitgebracht waarin wordt aanbevolen Opzelura® (ruxolitinib)-crème goed te keuren voor de behandeling van matige atopische dermatitis (AD) bij volwassen patiënten voor wie lokale corticosteroïden (TCS) en lokale calcineurineremmers (TCI) onvoldoende effectief of niet geschikt...

MORGES, Svizzera--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) oggi ha annunciato che il Comitato per i prodotti medicinali per uso umano (CHMP) dell'Agenzia Europea per i Medicinali (EMA) ha espresso un'opinione positiva sul farmaco, raccomandando l'approvazione di Opzelura® (ruxolitinib) crema per il trattamento della dermatite atopica (DA) moderata in pazienti adulti per i quali i corticosteroidi topici (TCS) e gli inibitori topici della calcineurina (TCI) sono inadeguati o inadatti. Il testo orig...

MORGES, Suiza--(BUSINESS WIRE)--Incyte (Nasdaq: INCY) ha anunciado hoy que el Comité de Medicamentos de Uso Humano (Committee for Medicinal Products for Human Use, CHMP) de la Agencia Europea de Medicamentos (EMA) ha emitido un dictamen favorable en el que recomienda la autorización de la crema Opzelura® (ruxolitinib) para tratar la dermatitis atópica (DA) moderada en los pacientes adultos para quienes los corticosteroides tópicos (CT) y los inhibidores tópicos de la calcineurina (ITC) resultan...